This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
MOUNTAIN VIEW, Calif., Aug. 27, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that a review article has been published
Postgraduate Medicine examining the treatment of obesity in the primary-care setting. This manuscript presents available medical treatment options, including Qsymia
® (phentermine and topiramate extended-release) capsules CIV, to assist clinicians in addressing the medical needs of their patients who are overweight or obese.
George Bray, MD, MACP, MACE; Michelle Look, MD, FAAFP; Donna Ryan, MD
"Treatment of Obesity in Primary Care: Targeting and Meeting Goals and Expectations (narrative review)"
According to the article, the primary-care provider should not only manage the common comorbidities related to obesity, but obesity itself must be recognized as a physical and physiologic state, requiring effective therapy and ongoing management.
® (phentermine and topiramate extended-release) capsules CIV is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m
2 or greater (obese) or 27 kg/m
2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.
The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.
Important Safety Information
Qsymia (phentermine and topiramate extended-release) capsules CIV is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in Qsymia.